Seattle-based Omeros Corp. is buying Nura in a deal that includes three venture capital groups -- some of the original investors in Nura -- making a "substantial investment" in Omeros. The merger will combine Nura's treatments for Parkinson's disease, schizophrenia and sleep disorders with Omeros' drug to reduce pain following arthroscopic surgery. Omeros is considering going public in 2007.

Full Story:

Related Summaries